The Usefulness of Assessing Heart Rate Variability in Patients With Acute Myocardial Infarction: From Primary Angioplasty to Secondary Long-term Prevention - a Single Centre, Prospective, Observational Cohort Study

The following data will be collected:

• general demographic data;
• time from chest pain onset to primary PCI;
• comorbidities (ischemic heart disease, arterial hypertension, previous PCI or coronary artery bypass surgery - CABG, heart failure, peripheral artery disease, atrial fibrillation, stroke, diabetes mellitus, kidney disease);
• cardiovascular risk factors (age, body mass index, smoking, abdominal perimeter, sedentarism, gender, inflammation);
• cardiac rhythm derived from electrocardiographic data;
• HRV time- and frequency domain parameters (respectively, SDNN, SDANN, RMSSD and LF, HF, LF/HF ratio);
• routine biological data and biomarkers, including creatine kinase-MB (CK-MB), aspartate transaminase (AST), lactate dehydrogenase (LDH) and cardiac-specific troponin;
• left ventricular ejection fraction at admission, at discharge and at follow-up (1 month, 6 months and 1 year);
• initial and final thrombolysis in myocardial infarction (TIMI) flow;
• type of stent used for coronary angioplasty;
• Global Registry of Acute Coronary Events (GRACE) score;
• SYNTAX score II in case of three-vessel coronary disease or involving left main stem;
• in-hospital, one month and long-term clinical outcomes (composite of all-cause mortality and major adverse cardiovascular events - MACE; ventricular arrhythmias; hospital admissions for heart failure; left ventricular systolic and diastolic disfunction; MACE in special subgroups of patients - elderly, diabetes mellitus, chronic kidney disease).